Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva Pharmaceutical and the Isreali-based subsidiary of Procognia have entered into a collaboration agreement for which Procognia will supply Teva with access to its glycoanalysis technology on an exclusive basis.
Subscribe to our email newsletter
Teva Pharmaceutical Industries will fund the costs of the collaboration and pay certain milestones and royalties to Procognia relating to the usage of the technology in the development of the biopharmaceuticals.
“We believe that accessing the Procognia technology will provide Teva with a distinct competitive advantage,” said Amir Elstein, group vice president, Global Specialty Pharmaceutical Products of Teva. He added, “Glyco-analysis is a complex task in producing biopharmaceuticals. Accessing the technology and skill set from Procognia should significantly benefit both the development and manufacturing processes.”
“The deal structure illustrates the potential advantages that our novel analytical platform can provide,” said Dr Shaike Yakir, president of Procognia.